Kevin Church - Mar 24, 2023 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
Chief Scientific Officer
Signature
Glenna Mileson, Attorney-in-fact for Kevin Church
Stock symbol
ATHA
Transactions as of
Mar 24, 2023
Transactions value $
$8,654
Form type
4
Date filed
3/27/2023, 04:57 PM
Previous filing
Jan 23, 2023
Next filing
Jan 8, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATHA Common Stock Options Exercise $8.65K +6.41K +10.33% $1.35 68.5K Mar 24, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATHA Stock Option (Right to Buy) Options Exercise $0 -6.41K -100% $0.00* 0 Mar 24, 2023 Common Stock 6.41K $1.35 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-fourth of the shares subject to the option vested on January 1, 2020 and one-fourth of the shares subject to the option vest on each year thereafter.